AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 179 filers reported holding AXSOME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $705,889 | -82.1% | 10,100 | -81.6% | 0.01% | -84.3% |
| Q2 2023 | $3,952,300 | +6.8% | 55,000 | -8.3% | 0.07% | -2.8% |
| Q1 2023 | $3,700,800 | -35.7% | 60,000 | -19.6% | 0.07% | -20.0% |
| Q4 2022 | $5,753,898 | -30.1% | 74,600 | -65.3% | 0.09% | -21.1% |
| Q2 2022 | $8,234,000 | -53.1% | 215,000 | -49.3% | 0.11% | -46.0% |
| Q1 2022 | $17,553,000 | +83.6% | 424,000 | +67.6% | 0.21% | +97.2% |
| Q4 2021 | $9,558,000 | +19.8% | 253,000 | +4.5% | 0.11% | +17.6% |
| Q3 2021 | $7,976,000 | -61.1% | 242,000 | -30.6% | 0.09% | -92.2% |
| Q1 2020 | $20,524,000 | +38.5% | 348,900 | +143.3% | 1.16% | +132.9% |
| Q4 2019 | $14,820,000 | +161.1% | 143,400 | -48.9% | 0.50% | +68.8% |
| Q3 2019 | $5,675,000 | +239.0% | 280,400 | +331.4% | 0.30% | +251.2% |
| Q2 2019 | $1,674,000 | +0.1% | 65,000 | -44.7% | 0.08% | -9.7% |
| Q1 2019 | $1,672,000 | – | 117,500 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |